Market Place
Sourcing Support
FDA approves record eight biosimilars in H1 2024; okays first interchangeable biosimilars for Eylea
Biologics, or complex drugs that are derived from living organisms, have revolutionized treatment of
America’s drug price hike conundrum in backdrop of 2019 Medicare Part D data
Nearly every
year, drugmakers ring in the new year with drug price increases in the US. This
year
Top drugs and pharmaceutical companies of 2019 by revenues
Acquisitions and spin-offs dominated headlines in 2019 and the tone was set very early with Bristol-
Biocon now in data integrity net; Chinese money on lookout for generic firms
This week, Phispers brings you more bad news from India’s Biocon, as Health Canada’s cau
Dr. Reddy’s fails EU inspection; Trump disbands business councils after Merck CEO and others quit it over intolerance
This week, Phispers brings you the high-pitched drama from President Trump’s American Manufact
Can Biocon-Mylan combine overcome its biosimilar program’s European inspection failure?
Last week, PharmaCompass
broke the story about Biocon’s biosimilar program suffering a se
Biocon`s biosimilars program fails European cGMP inspection
India’s pharma stocks have been taking
a beating of late due to compliance-related issues
J&J’s diabetes drug reduces heart risk at the cost of toes; Google’s AI eye doctor initiative
This week in Phispers, we bring you news on J&J’s Invokana, a drug that reduces heart risk
Top drugs by sales in 2016: Who sold the blockbuster drugs?
The year 2016 finished with a whimper insofar as mergers and acquisitions (M&As) were concerned.
Trump’s comments on drug prices sink pharma stocks; Teva lowers guidance by $ 1 billion
The New
Year began with the JP Morgan Healthcare Conference— the drug industry’s annual
